• About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • OncoFAP-Radio Conjugate
    • OncoFAP-Drug Conjugate
    • Onco IX (PHC-102, Imaging)
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering
  • About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • Onco IX (PHC-102, Imaging)
    • OncoFAP-Radio Conjugate
    • OncoFAP-Drug Conjugate
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering

Philogen to attend the Society for Immunotherapy of Cancer’s 37th Annual Meeting 2022 in Boston (8-12 November 2022)

by last | Nov 13, 2022 | Past Events

Philogen attends the SITC Annual Meeting in November 2022. Teresa Hemmerle, PhD, Senior Project Manager, to present an abstract entitled “Combinatorial chemoimmunotherapy based on the antibody-cytokine fusion protein L19TNF unleashes potent anti-tumor immunity against...

Philogen announces the publication of a new study in the European Journal of Nuclear Medicine and Molecular Imaging

by Lisa Nadal | Nov 11, 2022 | 2022, Past Events, Scientific

The study describes the discovery of GCPIII as the protein responsible for the accumulation of conventional PSMA targeting agents in healthy organs. More details

Philogen’s management team held a webinar on 29 September 2022 at 16:00 CEST

by last | Sep 28, 2022 | 2022, Past Events

Philogen held a virtual briefing on 29 September 2022 at 10:00 ET / 15:00 BST / 16:00 CEST following the Board of Directors’ approval of the Half-Yearly Financial Report as of 30 June 2022. Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief...

Philogen to attend the Peptide Therapeutic Forum 2022 on August 25-26, 2022

by last | Jul 6, 2022 | 2022, Past Events

Philogen announces its attendance at the Peptide Therapeutic Forum 2022. Samuele Cazzamalli, Head of Small Molecule Therapeutics at Philogen, is giving a lecture entitled “Small Molecule Therapeutics as an alternative to Peptide Therapeutics: a clean strategy to...

Philogen to attend the International Mass Spectrometry Congress 2022 in Maastricht (August 27th-September 2nd, 2022)

by last | Jul 6, 2022 | 2022, Past Events

Dr. Ettore Gilardoni, Head of Bio-MS at Philogen, will present a poster entitled: A mass spectrometry-based method for the determination of in vivo biodistribution of small molecule-metal conjugates. Dr. Gilardoni will also give a presentation on August 31st,...

Philogen to the 12th European Post-Chicago Melanoma/Skin Cancer Meeting, 30-1 July

by last | Jun 27, 2022 | 2022, Past Events

Philogen will be Bronze Sponsor of the Post-Chicago Meeting in Münich (30-1 July). Philogen will chair a Satellite Symposium on Friday July 1, 11.30-12.00 am. Dr. Alfredo Covelli, Philogen’s CMO, will give a presentation entitled “Immunocytokines for the therapy...
« Older Entries

Recent Posts

  • Philogen to attend the TIDES Europe 2022 in Vienna, Austria (16-18 November)
  • Philogen to attend the Society for Immunotherapy of Cancer’s 37th Annual Meeting 2022 in Boston (8-12 November 2022)
  • Philochem will be attending the 10th World ADC Conference in London
  • Philogen announces the publication of a new study in the European Journal of Nuclear Medicine and Molecular Imaging
  • Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands

Recent Comments

    Philochem AG ©

    Privacy / Contacts

    • Follow

    Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch